For pharmaceutical executives, investors, biosimilar developers, and healthcare strategists, few patent stories are as important as Dupixent. Developed by Sanofi and Regeneron Pharmaceuticals, Dupixent (dupilumab) has become one of the world’s most successful immunology therapies.
As annual sales continue to surge, the question is no longer whether competition will arrive, but when the patent wall will begin to crack and how large the commercial opportunity will be for competitors.
Why Dupixent Has Become a Blockbuster
Dupixent was initially launched for atopic dermatitis and has since expanded into multiple indications including asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, COPD, and chronic spontaneous urticaria.
The therapy targets IL-4 and IL-13 signaling pathways, helping control Type 2 inflammation across several chronic diseases.
The commercial results have been extraordinary. Global Dupixent sales reached approximately $14.15 billion in 2024, representing annual growth of more than 22%. By 2025, sales climbed further to nearly $17.8 billion worldwide, making it one of the highest-selling immunology drugs globally.
Understanding the Patent Expiration Timeline
The Dupixent patent landscape is more complex than a single expiration date.
Several patents protecting the product begin expiring in 2027, while broader patent protection extends much further into the future. Current patent databases indicate that the overall patent estate stretches to approximately 2042, depending on the specific patent family and jurisdiction.
However, industry observers often focus on 2031 because several key protections are expected to weaken around that period, creating a more realistic pathway for biosimilar competition. This is why many biosimilar developers are already investing heavily in dupilumab programs.
Dupixent Patent Snapshot
| Metric | Value |
|---|---|
| First patent expirations | 2027 |
| Major competitive focus year | 2031 |
| Latest reported patent protection | 2042 |
| 2024 Global Sales | $14.15 Billion |
| 2025 Global Sales | $17.8 Billion |
| Growth 2024–2025 | 26% |
| Companies | Sanofi & Regeneron |
The Massive Opportunity Awaiting Biosimilar Companies
The expiration of Dupixent patents represents one of the largest upcoming opportunities in biologics.
When blockbuster biologics lose exclusivity, biosimilars often capture billions of dollars in market value. Even a modest 15–20% market share of Dupixent’s future revenue could create a multi-billion-dollar business for a successful biosimilar entrant.
Several Asian and global pharmaceutical companies have already entered development programs. Korean drug manufacturers, in particular, have accelerated biosimilar research in anticipation of the expected 2031 patent cliff.
What This Means for Sanofi and Regeneron
For Sanofi, Dupixent has become the engine powering corporate growth.
The drug generated more than €13 billion in annual revenue and continues to receive approvals in new therapeutic areas. Management has publicly discussed ambitions for Dupixent sales to approach €22 billion by 2030, highlighting how critical the product remains to future earnings.
Looking for answers to your specific business questions? Our experts provide FREE customized sample reports: https://www.towardshealthcare.com/download-sample/5341
For Regeneron, Dupixent royalties and profit-sharing arrangements contribute significantly to financial performance. The company has repeatedly highlighted strong Dupixent growth as a key driver offsetting competitive pressure in other franchises.
Companies Watching the Patent Cliff Closely
Several pharmaceutical organizations are expected to be active participants in the future Dupixent biosimilar market:
- Samsung Bioepis
- Celltrion
- Amgen
- Sandoz
- Biocon Biologics
- KyungDong Pharm
Many of these organizations have established track records in biosimilar development and are expected to evaluate the Dupixent opportunity as patent barriers gradually decline.
Strategic Takeaway for Decision Makers
The Dupixent patent story is not simply about a drug losing exclusivity.
It represents a future market worth tens of billions of dollars, touching biologics manufacturing, biosimilar development, licensing, commercial partnerships, and healthcare pricing strategies.
While the first patent expirations begin in 2027, the more significant competitive window appears centered around 2031 and beyond. Until then, Sanofi and Regeneron are likely to continue strengthening their position through new indications, expanded patient populations, and additional intellectual property protections.
For executives planning long-term immunology strategies, Dupixent remains one of the most important patent cliffs of the next decade, with potential implications across the global pharmaceutical industry.
Access our exclusive, data-rich dashboard dedicated to the pharma industry – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting provides strategic intelligence and research expertise across the pharmaceutical market, including branded drugs, generic medicines, biologics, biosimilars, specialty pharmaceuticals, OTC products, and drug delivery systems. We support pharmaceutical companies with market analysis, pipeline assessment, and competitive insights to help drive innovation, strengthen commercialization strategies, and capture emerging growth opportunities in the evolving healthcare landscape.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium